A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 For Metastatic Breast Cancer.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Toxicity Based Upon Adverse Events Classifed by the NCI Common Terminology Criteria Version 3 (Phase 1)
Dose-Limiting Toxicities graded according to Common Terminology Criteria for Adverse Events, version 3.0
Deborah Grady, M.D.
University of California, San Francisco
United States: Food and Drug Administration